Rheumatology International 2020 March 23 [Link] Okamoto S, Tsuboi H, Sato R, Terasaki M, Terasaki T, Toko H, Shimizu M, Honda F, Yagishita M, Ohyama A, Kurata I, Abe S, Takahashi H, Osada A, Hagiwara S, Kondo Y, Matsumoto I, Sumida T Abstract IgG4-related disease (IgG4-RD) is a fibro-inflammatory condition characterized by increased serum IgG4 […]
April 6, 2020
American Journal of Industrial Medicine 2020 March 16 [Link] Emory TS, Maddox JC, Kradin RL Abstract BACKGROUND: Asbestos is the primary known cause of malignant mesothelioma. Some cosmetic talc products have been shown to contain asbestos. Recently, repeated exposures to cosmetic talc have been implicated as a cause of mesothelioma. METHODS: Seventy-five individuals (64 females; […]
March 30, 2020
Histopathology 2020 March 14 [Link] Bilecz A, Stockhammer P, Theegarten D, Kern I, Jakopovic M, Samarzija M, Klikovits T, Hoda MA, Döme B, Oberndorfer F, Muellauer L, Fillinger J, Kovács I, Pirker C, Schuler M, Plönes T, Aigner C, Klepetko W, Berger W, Brcic L, Laszlo V, Hegedus B Abstract AIMS: Malignant pleural mesothelioma (MPM) […]
March 27, 2020
Journal of Thoracic Oncology 2020 March 9 [Link] Salle FG, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R, […]
March 26, 2020
International Journal of Molecular Science 2020 March 7 [Link] Baldi A, De Luca A, Maiorano P, D’Angelo C, Giordano A Abstract Malignant mesothelioma is an infrequent tumor that initiates from the mesothelial cells lining of body cavities. The great majority of mesotheliomas originate in the pleural cavity, while the remaining cases initiate in the peritoneal […]
March 25, 2020
Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most […]
March 24, 2020
ESMO Open 2020 March [Link] Viscardi G, Di Liello R, Morgillo F Abstract Malignant pleural mesothelioma is a rare and aggressive malignancy mostly associated with occupational asbestos exposure. Prognosis is poor and only highly selected patients may benefit from aggressive surgical management, also as part of a multimodal approach. In advanced disease, the combination of […]
March 23, 2020
Anticancer Research 2020 March [Link] Sakata KI, Maeda K, Sakurai N, Liang S, Nakazawa S, Yanagihara K, Kubo T, Yoshiyama H, Kitagawa Y, Hamada JI, Iizasa H Abstract BACKGROUND/AIM: Malignant pleural mesothelioma (MPM) is an intractable cancer, and causes of its malignant transformation are not well known. Adenosine deaminase acting on RNA (ADAR) is an […]
March 20, 2020
Human Pathology 2020 March 3 [Link] Paajanen J, Laaksonen S, Kettunen E, Ilonen I, Vehmas T, Salo J, Räsänen J, Sutinen BHc E, Ollila BHc H, Mäyränpää MI, Myllärniemi M, Wolff H Abstract Diffuse malignant mesothelioma (DMM) of the pleura is a rare and aggressive disease, where the long-term survival (LTS) rate is low. The […]
March 18, 2020
Respirology 2020 March 2 [Link] Tsolaki V, Zarogiannis S, Zygoulis P, Kalomenidis I, Jagirdar R, Makris D, Daniil Z, Magkouta S, Triantafyllou I, Papanikolaou J, Gourgoulianis KI, Zakynthinos E Abstract BACKGROUND AND OBJECTIVE: Mesothelial cells and cardiomyocytes have shared embryonic mesodermal origin. Cardiomyocytes release BNP under stretch. We searched whether malignant mesothelioma cells also secrete […]
March 16, 2020